

## Improvement in the management of non muscle-invasive bladder cancer

Poster Session 17

Saturday, 12 March  
16:00 - 17:30

**Location:** Room 14b (ICM, Level 1)

**Chairs:** M. Babjuk, Prague (CZ)  
P. Gontero, Turin (IT)  
G. Simone, Rome (IT)

### Aims and objectives of this presentation

After primary transurethral resection of the bladder tumour (TURBT), adjuvant intravesical instillations are most commonly used to manage intermediate – high risk NMIBC. However, whether a preventive radical cystectomy (RC) should be performed in selected cases of high-grade T1 remains a moot point. The purpose of the session is to discuss current strategies according to recognised challenges in the field: increase the detection of bladder cancer and flat lesions, reduce residual tumours, reduce recurrence rate, prolongation of follow-up cystoscopies.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

\*203

### Modelling the burden of bladder cancer and monitoring cystoscopies in Europe

By: Vecino Ortiz A.I., Glover R., [Adams E.J.](#)

**Institutes:** Aquarius Population Health, Health Economics, London, United Kingdom

\*204

### Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle invasive bladder cancer

By: Onishi T.<sup>1</sup>, Sibahara T.<sup>1</sup>, Masui S.<sup>1</sup>, [Sugino Y.](#)<sup>1</sup>, Sasaki T.<sup>2</sup>

**Institutes:**<sup>1</sup>Ise Red Cross Hospital, Dept. of Urology, Ise, Japan, <sup>2</sup>Mie University Hospital, Dept. of Urology, Tsu, Japan

\*205

### Intravesical Bacillus Calmette-Guérin (BCG) versus combination of epirubicin and interferon- $\gamma$ 2a (EPI+INF) instillations in prevention of frequently recurrent non-muscle-invasive bladder carcinoma (NMIBC) - FinnBladder-6 study

By: [Marttila T.](#)<sup>2</sup>, Järvinen R.<sup>1</sup>, Seppänen M.<sup>3</sup>, Liukkonen T.<sup>4</sup>, Raitanen M.<sup>2</sup>, Boström P.<sup>5</sup>, Kaasinen E.<sup>6</sup>

**Institutes:**<sup>1</sup>Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, <sup>2</sup>Seinäjoki Central Hospital, Dept. of Urology, Seinäjoki, Finland, <sup>3</sup>Satakunta Central Hospital, Dept. of Urology, Pori, Finland, <sup>4</sup>Mikkeli Central Hospital, Dept. of Urology, Mikkeli, Finland, <sup>5</sup>Turku University Hospital, Dept. of Urology, Turku, Finland, <sup>6</sup>Hyvinkää Hospital, Dept. of Urology, Hyvinkää, Finland

\*206

### Cancer-specific survival in patients with primary bladder CIS

By: [Jancke G.](#)

**Institutes:** Skånes Universitetssjukhus, Dept. of Urology, Malmö, Sweden

\*207

### 3rd course of BCG instillation to the patients with primary CIS of bladder: Is it safe?

By: [Kim S.J.](#)<sup>1</sup>, Hong S.<sup>2</sup>, Kim H.J.<sup>2</sup>, You D.<sup>1</sup>, Jeong I.G.<sup>1</sup>, Song C.<sup>1</sup>, Hong B.S.<sup>1</sup>, Kim C.S.<sup>1</sup>, Ahn H.<sup>1</sup>, Hong J.H.<sup>1</sup>

**Institutes:**<sup>1</sup>Asan Medical Center, Dept. of Urology, Seoul, South Korea, <sup>2</sup>Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea

\*208

### Transurethral resection guided by photodynamic diagnosis can prevent progression in non-muscle invasive bladder cancer patients

By: [Rolevich A.I.](#)<sup>1</sup>, Zhegalik A.G.<sup>1</sup>, Minich A.A.<sup>1</sup>, Nabebina T.I.<sup>2</sup>, Polyakov S.A.<sup>1</sup>, Krasny S.A.<sup>1</sup>,

Sukonko O.G.<sup>1</sup>

**Institutes:**<sup>1</sup>N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Urology, Minsk, Belarus, <sup>2</sup>N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Pathology, Minsk, Belarus

\*209

**A phase 1 clinical trial assessing an intravesical administered second-generation antisense oligonucleotide targeting heat shock protein 27 in bladder cancer**

**By:** Frees S., Beraldi E., Chi K., Fazli L., Black P., Gleave M., So A.

**Institutes:**Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

\*210

**Randomized study of intravesical chemotherapy using pirarubicin in low- and intermediate risk non-muscle-invasive bladder cancer in Japan - comparison one immediate postoperative intravesical chemotherapy with short-term adjuvant intravesical chemotherapy after TURBT**

**By:** Naya Y.<sup>1</sup>, Shiraishi T.<sup>1</sup>, Oishi M.<sup>1</sup>, Ueda T.<sup>1</sup>, Nakanishi H.<sup>1</sup>, Nakamura T.<sup>1</sup>, Hongo F.<sup>1</sup>, Iwata T.<sup>2</sup>, Kanazawa M.<sup>3</sup>, Mikami K.<sup>4</sup>, Kamoi K.<sup>1</sup>, Okihara K.<sup>1</sup>, Ukimura O.<sup>1</sup>

**Institutes:**<sup>1</sup>Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, <sup>2</sup>Nantan Hospital, Dept. of Urology, Nantan, Japan, <sup>3</sup>Matsushita Memorial Hospital, Dept. of Urology, Moriguchi, Japan, <sup>4</sup>Kyoto First Red-Cross Hospital, Dept. of Urology, Kyoto, Japan

\*211

**Decrease in rate of Tx histology after transurethral resection of bladder tumours following implementation of an institutional quality improvement programme**

**By:** Giannarini G., Crestani A., Palumbo V., Calandriello M., Abbinante M., Ficarra V.

**Institutes:**Academic Medical Centre Hospital Santa Maria Della Misericordia, Dept. of Urology, Udine, Italy

\*212

**White light imaging vs Storz Professional Image Enhancement System (SPIES) cystoscopy during follow up of patients submitted to WLI-transurethral resection of non-muscle-invasive bladder cancer: Preliminary results of a bicenter randomized diagnostic trial**

**By:** Chondros K.<sup>1</sup>, Kazoulis S.<sup>2</sup>, Chrysanthakopoulos G.<sup>2</sup>, Tamiolakis D.<sup>3</sup>, Kalogeraki A.<sup>3</sup>, Tzardi M.<sup>3</sup>, Heretis I.<sup>1</sup>, Mavromanolakis E.<sup>1</sup>, Chondros N.<sup>1</sup>, Zoras O.<sup>4</sup>, Chalkiadakis G.<sup>5</sup>, Mamoulakis C.<sup>1</sup>

**Institutes:**<sup>1</sup>University General Hospital of Heraklion, Dept. of Urology, Heraklion, Greece, <sup>2</sup>General Hospital of Chania St. George, Dept. of Urology, Chania, Greece, <sup>3</sup>University General Hospital of Heraklion, Dept. of Pathology-Cytopathology, Heraklion, Greece, <sup>4</sup>University General Hospital of Heraklion, Dept. of Surgical Oncology, Heraklion, Greece, <sup>5</sup>University General Hospital of Heraklion, Dept. of General Surgery, Heraklion, Greece

\*213

**Visualizing the muscularis propria via narrow band imaging during transurethral en bloc dissection for non-muscle-invasive bladder cancer**

**By:** Okada Y., Kawakami S., Takeshita H., Yano A., Chou E., Sugiyama H., Morozumi M., Yamada T.

**Institutes:**Saitama Medical Center, Dept. of Urology, Saitama, Japan

\*214

**Prognostic significance of markers of systemic inflammatory response in patients with non-muscle invasive bladder cancer**

**By:** Mbeutcha A.<sup>1</sup>, Shariat S.<sup>2</sup>, Rieken M.<sup>3</sup>, Rink M.<sup>4</sup>, Xylinas E.<sup>5</sup>, Seitz C.<sup>2</sup>, Lucca I.<sup>6</sup>, Mathieu R.<sup>7</sup>, Rouprêt M.<sup>8</sup>, Briganti A.<sup>9</sup>, Karakiewicz P.<sup>10</sup>, Klatte T.<sup>2</sup>

**Institutes:**<sup>1</sup>University Hospital of Nice, Dept. of Urology, Nice, France, <sup>2</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>3</sup>University Hospital of Basel, Dept. of Urology, Basel, Switzerland, <sup>4</sup>University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, <sup>5</sup>Cochin Hospital, APHP, Paris Descartes University, Dept. of Urology, Paris, France, <sup>6</sup>Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, <sup>7</sup>Rennes University Hospital, Dept. of Urology, Rennes, France, <sup>8</sup>Pitié- Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, <sup>9</sup>Università Vita-Salute, Ospedale S. Raffaele, Dept. of Urology, Milan, Italy, <sup>10</sup>University of Montréal, Dept. of Urology, Montréal, Canada

\*215

**A phase II trial of an oral methionine aminopeptidase II (MetAP2) inhibitor for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who relapsed after intravesical therapies: Preliminary results**

**By:** Yao X.<sup>2</sup>, Wang G.<sup>3</sup>, Pu J.<sup>4</sup>, Yao X.<sup>5</sup>, Zhou F.<sup>6</sup>, Qi J.<sup>7</sup>, Ye Z.<sup>8</sup>, Xie L.<sup>9</sup>, Chen J.<sup>10</sup>, Xie K.<sup>11</sup>, Zhao X.<sup>12</sup>, Xu Z.<sup>13</sup>, Guo H.<sup>14</sup>, Yang Y.<sup>15</sup>, Cao D.<sup>1</sup>, Yang B.<sup>2</sup>, Zhang C.<sup>3</sup>, Lu Y.<sup>4</sup>, Du J.<sup>5</sup>, Ye Y.<sup>6</sup>, Gu Z.<sup>7</sup>, Song X.<sup>8</sup>, Liu

B.<sup>9</sup>, Wen J.<sup>10</sup>, Deng X.<sup>11</sup>, Zhong Z.<sup>12</sup>, Liao G.<sup>13</sup>, Liu T.<sup>14</sup>, Zhao Q.<sup>15</sup>, Jia Y.<sup>16</sup>, Liu J.<sup>17</sup>, Pan K.<sup>16</sup>, Ye D.<sup>1</sup>  
**Institutes:**<sup>1</sup>Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, <sup>2</sup>Shanghai The Tenth People's Hospital of Tongji University, Dept. of Urology, Shanghai, China, <sup>3</sup>The First Affiliated Hospital of Nanchang University, Dept. of Urology, Nanchang, China, <sup>4</sup>The First Affiliated Hospital of Soochow University, Dept. of Urology, Suzhou, China, <sup>5</sup>Tianjin Medical University Cancer Institute & Hospital, Dept. of Urology, Tianjin, China, <sup>6</sup>Sun Yat-Sen University Cancer Center, Dept. of Urology, Guangzhou, China, <sup>7</sup>Xin Hua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, <sup>8</sup>Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Dept. of Urology, Wuhan, China, <sup>9</sup>The First Affiliated Hospital, Zhejiang University, Dept. of Urology, Hangzhou, China, <sup>10</sup>The Second Affiliated Hospital of Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China, <sup>11</sup>Guangzhou The First People's Hospital, Dept. of Urology, Guangzhou, China, <sup>12</sup>The Second Xiangya Hospital of Central South University, Dept. of Urology, Changsha, China, <sup>13</sup>Zhejiang Provincial People's Hospital, Dept. of Urology, Hangzhou, China, <sup>14</sup>Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, <sup>15</sup>Beijing Cancer Hospital, Dept. of Urology, Beijing, China, <sup>16</sup>Jiangsu Yahong MediTech Co., Ltd., Dept. of Clinical Research, Taizhou, China, <sup>17</sup>Jiangsu Yahong MediTech Co., Ltd., Pharmaceutical Sciences, Taizhou, China

\*216

**Discrepancy between guidelines and daily practice in the management of non-muscle-invasive bladder cancer (NMIBC): Results of a European survey**

**By:** Aziz A.<sup>2</sup>, Bes P.<sup>12</sup>, Chun F.K.<sup>2</sup>, Dobruch J.<sup>3</sup>, Kluth L.A.<sup>2</sup>, Gontero P.<sup>4</sup>, Necchi A.<sup>5</sup>, Noon A.<sup>6</sup>, Van Rhijn B.WG<sup>7</sup>, Rink M.<sup>2</sup>, Roghmann F.<sup>8</sup>, Roupert M.<sup>9</sup>, Seiler R.<sup>10</sup>, Shariat S.F.<sup>11</sup>, Qvick B.<sup>12</sup>, Xylinas E.N.<sup>1</sup>

**Institutes:**<sup>1</sup>Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, <sup>2</sup>University Medical Center Hamburg-Eppendorf, Hamburg, Dept. of Urology, Hamburg, Germany, <sup>3</sup>Centre of Postgraduate Medical Education, Dept. of Urology, Warsaw, Poland, <sup>4</sup>Città Della Salute E Della Scienza Di Torino, Dept. of Urology, Turin, Italy, <sup>5</sup>Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, <sup>6</sup>Division of Urology, University of Toronto, Dept. of Urology, Toronto, Canada, <sup>7</sup>Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, <sup>8</sup>Marien Hospital, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, <sup>9</sup>Pitié-Salpêtrière APHP, Dept. of Urology, Paris, France, <sup>10</sup>University of Berne, Dept. of Urology, Berne, Switzerland, <sup>11</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>12</sup>Ipsen, Dept. of Pharma, Paris, France